Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

Cancer Research

Volumn 61, Issue 11, 2001, Pages 4432-4436

  Morony, S ^a   Capparelli, C ^a   Sarosi, I ^a   Lacey, D L ^a   Dunstan, C R ^a   Kostenuik, P J ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE LESION; BONE METASTASIS; CANCER CELL CULTURE; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, NUDE; OSTEOLYSIS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035360265     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone
2. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats
3. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
4. Inhibition of osteolytic bone metastasis of breast cancer cells by combined treatment with bisphosphonate ibandronate and tissue inhibitor of matrix metalloproteinase-2
5. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice
6. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone
7. Breast cancer cells interact with osteoblasts to support osteoclast formation
8. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor
9. Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3
10. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
11. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
12. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
13. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
14. Trance is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
15. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis
16. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
17. Rank is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism
18. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
19. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
20. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
21. Mechanisms of paraneoplastic syndromes of colon-26: Involvement of interleukin 6 in hypercalcemia
22. A murine model of experimental metastasis to bone and bone marrow
23. 3
24. Chemotactic responses of tumor cells to products of resorbing bone